STSM Report: Joanna Wielińska
STSM Reports Published on 18th February 2020
I am Joanna Wielińska, a PhD student in Professor Katarzyna Bogunia-Kubik’s Laboratory of Clinical Immunogenetics and Pharmacogenetics at the Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw, Poland.
I am Joanna Wielińska, a PhD student in Professor Katarzyna Bogunia-Kubik’s Laboratory of Clinical Immunogenetics and Pharmacogenetics at the Hirszfeld Institute of Immunology and Experimental Therapy in Wroclaw, Poland. I participated in a short term scientific mission (STSM) on “Molecular and Cellular Biomarkers of Chronic Graft versus Host Disease (cGvHD)” for three weeks in Newcastle in July 2019. The STSM refers to Working Group 2, conducted by Professor Anne Dickinson from Newcastle University.
The main goal of this STSM was to perform the screening of miRNA molecules of selected clinical samples from patients with and without chronic GvHD symptoms, using the NanoString technology. I was supervised by Dr Rachel Crossland in the Haematological Sciences Department during this STSM. I performed laboratory work including extracellular vesicle (EV) precipitation from serum and plasma GvHD samples and then total RNA isolation. Next, I measured the RNA concentrations on Bioanalyzer and used this RNA as input material in NanoString technology. Successfully, I was able to perform miRNA screening in patients with different clinical features. What is more, I analysed the isolated EVs employing electron microscopy as well as NanoSight vesicle tracking analysis.
During my stay, I took part in the processing of NanoString data with Piotr Łacina, who performed the analytical part of this experiment. He evaluated raw output data using nSolver Analysis Software and RStudio to assess the miRNA repertoire of cGvHD and non-cGvHD patients.
The STSM at Newcastle University has been a unique opportunity to gain practical and theoretical knowledge about NanoString technology. During my stay, I learnt how to prepare samples, perform miRNAs expression and analyse the data, which was a new experience for me. Unbounded technology potential can be used to identify molecular biomarkers in other prospective COST collaborative studies.